Cerebral protective and cognition-improving effects of sinapic acid in rodents.
We previously demonstrated that tenuifoliside B and 3,6'-disinapoylsucrose in Polygalae Radix, the root of Polygala tenuifolia WILLDENOW, inhibited potassium cyanide (KCN)-induced hypoxia and scopolamine-induced memory impairment in mice. Because both ingredients have a common sinapoyl moiety in their structure, we inferred that the sinapoyl moiety could inhibit hypoxia and memory impairment. In the present study to clarify the hypothesis, sinapic acid inhibited KCN-induced hypoxia and scopolamine-induced memory impairment as well as tenuifoliside B and 3,6'-disinapoylsucrose did. In addition, sinapic acid inhibited decompression- or bilateral carotid artery ligation-induced hypoxia (or mortality) and CO2-induced impairment in mice, and basal forebrain lesion-induced cerebral cholinergic dysfunction (decreases in acetylcholine concentration and choline acetyltransferase activity) in rats. These results, taken together, suggest the possibilities that sinapic acid is not only a very important moiety in the pharmacological activities of tenuifoliside B and 3,6'-disinapoylsucrose but also a candidate for a cerebral protective and cognition-improving medicine.
Karakida
Fumito
F
Central Research Laboratory, Tsumura & Co., 3586 Yoshiwara Ami-machi, Inashiki-gun, Ibaraki 300-1192, Japan.
Ikeya
Yukinobu
Y
Tsunakawa
Mitsuo
M
Yamaguchi
Takuji
T
Ikarashi
Yasushi
Y
Takeda
Shuichi
S
Aburada
Masaki
M
D000109:Acetylcholine / Q000378:metabolism; D000647:Amnesia / Q000139:chemically induced / Q000517:prevention & control; D000818:Animals; D002245:Carbon Dioxide / Q000008:administration & dosage / Q000633:toxicity; D003071:Cognition / Q000187:drug effects* / Q000502:physiology; D003128:Coma / Q000139:chemically induced / Q000517:prevention & control; D003373:Coumaric Acids / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D018690:Excitatory Amino Acid Agonists / Q000008:administration & dosage / Q000633:toxicity; D005625:Frontal Lobe / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D000860:Hypoxia / Q000209:etiology / Q000517:prevention & control; D007051:Ibotenic Acid / Q000008:administration & dosage / Q000633:toxicity; D008297:Male; D020835:Medicine, Kampo; D008569:Memory Disorders / Q000503:physiopathology / Q000517:prevention & control*; D051379:Mice; D008813:Mice, Inbred ICR; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D010296:Parietal Lobe / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D011190:Potassium Cyanide / Q000008:administration & dosage / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D012601:Scopolamine / Q000008:administration & dosage / Q000633:toxicity; D015996:Survival Rate
D003373:Coumaric Acids; D018690:Excitatory Amino Acid Agonists; D018696:Neuroprotective Agents; D002245:Carbon Dioxide; D007051:Ibotenic Acid; C073734:sinapinic acid; D012601:Scopolamine; D011190:Potassium Cyanide; D000109:Acetylcholine